Recommendations for Biomarker Identification and Qualification in Clinical Proteomics

Mischak, Harald; Allmaier, Günter; Apweiler, Rolf; Attwood, Teresa K.; Baumann, Marc; Benigni, Ariela; Bennett, Samuel; Bischoff, Rainer; Bongcam‐Rudloff, Erik; Capasso, Giovambattista; Coon, Joshua J.; D’Haese, Patrick C.; Dominiczak, Anna F.; Dakna, Mohammed; Dihazi, Hassan; Ehrich, J. H. H.; Fernández-Llama, Patricia; Fliser, Danilo; Frøkiær, Jørgen; Garin, Jérôme; Girolami, Mark; Hancock, William S.; Haubitz, Marion; Hochstrasser, Denis F.; Holman, Rury R.; Ioannidis, John P. A.; Jankowski, Joachim; Julian, Bruce A.; Klein, Jon B.; Kölch, Walter; Luider, Theo M.; Massy, Ziad A.; Mattes, William B.; Molina, Franck; Monsarrat, Bernard; Novák, Jan; Peter, Karlheinz; Rossing, Peter; Sänchez‐Carbayo, Marta; Schanstra, Joost P.; Semmes, O. John; Spasovski, Goce; Theodorescu, Dan; Thongboonkerd, Visith; Vanholder, Raymond; Veenstra, Timothy D.; Weissinger, Eva M.; Yamamoto, Tadashi; Vlahou, Antonia

doi:10.1126/scitranslmed.3001249

Cited by 286 publications

(231 citation statements)

References 34 publications

Supporting

Mentioning

224

Contrasting

Order By: Relevance

“…Accuracy, reproducibility, availability, feasibility of implementation into the clinical settings, sensitivity and specificity are additional characteristics to be fulfilled, and panels of biomarkers are gaining acceptance instead of individual molecules (112) , as single biomarkers are often not available and lack the ability to adequately describe complex diseases (113) . Candidate biomarkers should be carefully validated in a wide and different cohort of samples from those used in the discovery phase as often overfitting of the biomarker model has occurred (114) . The proteome, corresponding to a set of expressed proteins, informs the current 'status' of an organism, constantly changing according to endogenous and exogenous factors (113) .…”

Section: Proteomics Biomarkers As a Mechanistic Approach To Explain Omentioning

confidence: 99%

New perspectives on bioactivity of olive oil: evidence from animal models, human interventions and the use of urinary proteomic biomarkers

et al. 2015

View full text Add to dashboard Cite

Olive oil (OO) is the primary source of fat in the Mediterranean diet and has been associated with longevity and a lower incidence of chronic diseases, particularly CHD. Cardioprotective effects of OO consumption have been widely related with improved lipoprotein profile, endothelial function and inflammation, linked to health claims of oleic acid and phenolic content of OO. With CVD being a leading cause of death worldwide, a review of the potential mechanisms underpinning the impact of OO in the prevention of disease is warranted. The current body of evidence relies on mechanistic studies involving animal and cell-based models, epidemiological studies of OO intake and risk factor, small-and large-scale human interventions, and the emerging use of novel biomarker techniques associated with disease risk. Although model systems are important for mechanistic research nutrition, methodologies and experimental designs with strong translational value are still lacking. The present review critically appraises the available evidence to date, with particular focus on emerging novel biomarkers for disease risk assessment. New perspectives on OO research are outlined, especially those with scope to clarify key mechanisms by which OO consumption exerts health benefits. The use of urinary proteomic biomarkers, as highly specific disease biomarkers, is highlighted towards a higher translational approach involving OO in nutritional recommendations.

show abstract

Section: Proteomics Biomarkers As a Mechanistic Approach To Explain Omentioning

confidence: 99%

New perspectives on bioactivity of olive oil: evidence from animal models, human interventions and the use of urinary proteomic biomarkers

et al. 2015

View full text Add to dashboard Cite

show abstract

“…A proteomic biomarker is defined as 'a specific peptide/protein that is associated with a specific condition, such as the onset, the manifestation, or progression of a disease or a response to treatment' [41]. Proteomics biomarker discovery developed over ten years ago in neurodegeneration diseases such as AD, PD, and ALS, but more biomarkers for neurodegenerative disorders identification are needed.…”

Section: Mass Spectrometry (Ms) Is Providing a Usefulmentioning

confidence: 99%

“…Proteomics biomarker discovery developed over ten years ago in neurodegeneration diseases such as AD, PD, and ALS, but more biomarkers for neurodegenerative disorders identification are needed. Six plasma biomarkers were identified in AD patients by plasma proteomic study using 2D-GE and LC/GC/MS, and one of them is α-1 antitrypsin, which has higher expression level using ELISA in plasma of AD patients [39][40][41][42].…”

Section: Mass Spectrometry (Ms) Is Providing a Usefulmentioning

confidence: 99%

Proteomics Analysis for Therapeutic Options of Neurodegeneration: A Review

Ganash¹

2017

J Proteomics Bioinform

View full text Add to dashboard Cite

“…It is unlikely that this level of complexity can be quantitatively assessed by one or a few specific proteins or metabolites in a way that supports robust diagnosis. Third, many of the biomarkers that have been proposed are of low stability or require substantial preassay purification or preparation; these aspects introduce substantial variation into the measured values (1,2). As a result, although considerable effort has been put into the development of biomarkers, only a small fraction of candidates make it to clinical practice, and the utility of those that are used is sometimes only modest (3)(4)(5).…”

mentioning

confidence: 99%

Immunosignature system for diagnosis of cancer

Stafford

Cichacz

Woodbury

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Although the search for disease biomarkers continues, the clinical return has thus far been disappointing. The complexity of the body's response to disease makes it difficult to represent this response with only a few biomarkers, particularly when many are present at low levels. An alternative to the typical reductionist biomarker paradigm is an assay we call an "immunosignature." This approach leverages the response of antibodies to diseaserelated changes, as well as the inherent signal amplification associated with antigen-stimulated B-cell proliferation. To perform an immunosignature assay, the antibodies in diluted blood are incubated with a microarray of thousands of random sequence peptides. The pattern of binding to these peptides is the immunosignature. Because the peptide sequences are completely random, the assay is effectively disease-agnostic, potentially providing a comprehensive diagnostic on multiple diseases simultaneously. To explore the ability of an immunosignature to detect and identify multiple diseases simultaneously, 20 samples from each of five cancer cohorts collected from multiple sites and 20 noncancer samples (120 total) were used as a training set to develop a reference immunosignature. A blinded evaluation of 120 blinded samples covering the same diseases gave 95% classification accuracy. To investigate the breadth of the approach and test sensitivity to biological diversity further, immunosignatures of >1,500 historical samples comprising 14 different diseases were examined by training with 75% of the samples and testing the remaining 25%. The average accuracy was >98%. These results demonstrate the potential power of the immunosignature approach in the accurate, simultaneous classification of disease.cancer diagnostic | immunodiagnostic | antibody biomarker | peptide microarray

show abstract

Recommendations for Biomarker Identification and Qualification in Clinical Proteomics

Abstract: Recommendations about structuring proteomic biomarker studies should increase the probability that such markers will be clinically useful.

Cited by 286 publications

References 34 publications

New perspectives on bioactivity of olive oil: evidence from animal models, human interventions and the use of urinary proteomic biomarkers

New perspectives on bioactivity of olive oil: evidence from animal models, human interventions and the use of urinary proteomic biomarkers

Proteomics Analysis for Therapeutic Options of Neurodegeneration: A Review

Immunosignature system for diagnosis of cancer

Contact Info

Product

Resources

About